Clene INC

Clene Inc. announced Q2 2026 results, highlighting progress towards an ALS drug NDA submission and providing an operating runway through late Q4 2026, alongside financial updates.

Clene Inc. announced new biomarker analyses from its CNM-Au8 trials, showing a correlation between NfL biomarker response and improved survival and function in ALS patients, which will be included in its upcoming NDA submission for accelerated approval.

Clene Inc. has deferred debt payments and received shareholder approval to increase its 2020 Stock Plan by 1 million shares.

Clene Inc. announced a second amendment to its senior secured convertible promissory notes, extending the maturity date and deferring payments, alongside positive updates on its CNM-Au8 program for ALS, targeting a Q3 2026 NDA submission.

Clene Inc. has priced an underwritten offering of 1,000,000 shares of common stock at $7.00 per share to raise approximately $6.4 million in net proceeds.

Clene Inc. announced it will file an accelerated approval New Drug Application (NDA) for its ALS treatment, CNM-Au8, following a successful meeting with the FDA.

Clene Inc. reported significant net losses and cash outflows in its Q2 2026 10-Q filing, raising substantial doubt about its ability to continue as a going concern.

Clene Inc. reports Q1 2026 results, highlighting progress in ALS and MS drug development, while facing ongoing financial challenges and a going concern assessment.

Clene Inc. reported a reduced net loss in Q3 2025 and advanced its CNM-Au8 clinical programs for ALS and MS, but faces substantial doubt about its ability to continue as a going concern.

Clene Inc. reported a reduced net loss in Q2 2025, while continuing to advance its lead drug candidate CNM-Au8 for ALS and MS, despite ongoing liquidity concerns and internal control weaknesses.

Clene Inc. reports a net loss of $751,000 for Q1 2025, provides updates on its clinical programs, and acknowledges substantial doubt about its ability to continue as a going concern.

Clene Inc. reported its financial results for the third quarter of 2024, highlighting ongoing clinical trials and a recent capital raise, while also acknowledging substantial doubt about its ability to continue as a going concern.

Clene Inc. reports strong clinical data for its lead drug candidate CNM-Au8 in ALS, paving the way for an accelerated FDA approval pathway by mid-2026, despite ongoing financial challenges.

Clene Inc. details its 2024 financial results and provides an update on its regulatory strategy for CNM-Au8, its lead drug candidate for ALS.

Clene Inc.'s annual 10-K filing provides a comprehensive overview of the company's capital structure, outstanding warrants, and financial position, highlighting its focus on developing novel nanotherapeutics.

Matthew Kiernan, a Director of Clene Inc., received 3,195 shares of common stock on August 13, 2026.

Arjun Jj Desai, a Director of Clene Inc., received 3,674 shares of common stock on August 13, 2026.

Alison Mosca, a Director of Clene Inc., received 4,872 shares of common stock on August 13, 2026.

David J Matlin, a Director of Clene Inc., received 6,230 shares of common stock on August 13, 2026.

Shalom Jacobovitz, a Director of Clene Inc., received 4,752 shares of common stock on August 13, 2026.

Jonathon Gay, a Director of Clene Inc., received 3,794 shares of common stock on August 13, 2026.

Clene Inc. has filed a definitive proxy statement with the Securities and Exchange Commission.

Clene Inc. is holding its 2025 Annual Meeting of Stockholders to vote on key proposals including director elections, auditor ratification, executive compensation, and an amendment to the company's stock plan.

Clene Inc. has filed a definitive proxy statement with the Securities and Exchange Commission.

Clene Inc. is asking stockholders to vote on proposals including increasing authorized shares, a reverse stock split, director elections, auditor ratification, and executive compensation at its upcoming annual meeting.

Vivo Opportunity entities have reported beneficial ownership of 9.99% of Clene Inc.'s common stock, primarily through exercisable warrants.

Chidozie Ugwumba has reported a complete divestment of all beneficial ownership in Clene Inc., ceasing to have voting or investment power over the company's holdings.

Empery Asset Management, LP, through its managed funds, has acquired a beneficial ownership of 916,532 shares, representing 7.17% of Clene Inc.'s common stock, as of June 30, 2026.

Investor Chidozie Ugwumba has filed a Schedule 13G reporting a 9.7% beneficial ownership stake in Clene Inc. common stock.

Alison Mosca has filed an amended Schedule 13G reporting a 13% beneficial ownership stake in Clene Inc. common stock.

Chidozie Ugwumba has filed an amendment to his Schedule 13G, reporting beneficial ownership of 1,915,650 shares of Clene Inc. common stock.